Literature DB >> 3924747

Intestinal permeability to 51Cr-EDTA in rats with experimentally induced enteropathy.

I Bjarnason, P Smethurst, A J Levi, T J Peters.   

Abstract

Intestinal permeability has been investigated in the normal rat by measuring the five hour urine excretion of 51Cr-EDTA after intragastric administration. Twelve control animals excreted 2.06% +/- 0.22 (mean +/- SE) of the administered dose. Prolonged intestinal transit times with atropine had no significant effect on the apparent permeability with a urine excretion 2.31% +/- 0.36. The concomitant administration of a hypertonic, but rapidly absorbed glycerol solution, was accompanied by increased urinary excretion (3.05% +/- 0.33) while the administration of a poorly absorbed sugar, lactulose, significantly decreased the apparent permeability (urine excretion 0.61% +/- 0.14) showing that passive intestinal permeability estimations are affected by test dose composition. Enteropathy was induced by ethanol, cetrimide, or methotrexate and each was associated with increased permeability, with urine excretions of 4.19% +/- 0.47, 4.20% +/- 0.66 and 3.97% +/- 0.49 respectively. It is thus suggested that the normal rat mucosa is maximally resistant to the absorption of foreign compounds such as 51Cr-EDTA and intestinal damage will disrupt this barrier.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924747      PMCID: PMC1432753          DOI: 10.1136/gut.26.6.579

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  39 in total

1.  Antigen absorption from the small intestine and gastrointestinal disease.

Authors:  W A Walker
Journal:  Pediatr Clin North Am       Date:  1975-11       Impact factor: 3.278

2.  Small intestinal absorption of horseradish peroxidase. A cytochemical study.

Authors:  R Cornell; W A Walker; K J Isselbacher
Journal:  Lab Invest       Date:  1971-07       Impact factor: 5.662

3.  Small intestinal damage and changes in cell population produced by ethanol ingestion in the rat.

Authors:  E Barona; R C Pirola; C S Leiber
Journal:  Gastroenterology       Date:  1974-02       Impact factor: 22.682

4.  Osmotic opening of tight junctions in cerebral endothelium.

Authors:  M W Brightman; M Hori; S I Rapoport; T S Reese; E Westergaard
Journal:  J Comp Neurol       Date:  1973-12-15       Impact factor: 3.215

5.  Circulating immune complexes in ulcerative colitis and Crohn's disease.

Authors:  D P Jewell; I C Maclennan; S C Truelove
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

6.  Further observations on asymmetrical solute movement across membranes.

Authors:  T J Franz; W R Galey; J T Van Bruggen
Journal:  J Gen Physiol       Date:  1968-01       Impact factor: 4.086

7.  A comparative study of the toxic effects of calcium and chromium chelates of ethylenediaminetetraacetate in the dog.

Authors:  F A Ahrens; A L Aronson
Journal:  Toxicol Appl Pharmacol       Date:  1971-01       Impact factor: 4.219

8.  Permeability characteristics of the human small intestine.

Authors:  J S Fordtran; F C Rector; M F Ewton; N Soter; J Kinney
Journal:  J Clin Invest       Date:  1965-12       Impact factor: 14.808

9.  Anomalous transport of electrolytes and sucrose through the isolated frog skin induced by hypertonicity of the outside bathing solution.

Authors:  H H Ussing
Journal:  Ann N Y Acad Sci       Date:  1966-07-14       Impact factor: 5.691

10.  Effect of calcium and chromium chelates of ethylenediaminetetraacetate on intestinal permeability and collagen metabolism in the rat.

Authors:  A L Aronson; K M Rogerson
Journal:  Toxicol Appl Pharmacol       Date:  1972-04       Impact factor: 4.219

View more
  23 in total

1.  Intestinal tolerability of nitroxybutyl-flurbiprofen in rats.

Authors:  S Somasundaram; S Rafi; M Jacob; G Sigthorsson; T Mahmud; R Sherwood; A B Price; A Macpherson; D Scott; J M Wrigglesworth; I Bjarnason
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  Enteral glutamine pretreatment does not decrease plasma endotoxin level induced by ischemia-reperfusion injury in rats.

Authors:  Arda Demirkan; Erkin Orazakunov; Berna Savaş; M Ayhan Kuzu; Mehmet Melli
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

3.  Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism.

Authors:  A Z Leite; A M Sipahi; A O Damião; A M Coelho; A T Garcez; M C Machado; C A Buchpiguel; F P Lopasso; M L Lordello; C L Agostinho; A A Laudanna
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Vindaloo and you.

Authors: 
Journal:  BMJ       Date:  1989-02-04

5.  Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat.

Authors:  M H Perdue; J K Ramage; D Burget; J Marshall; S Masson
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

6.  Intestinal permeability during chemotherapy for childhood tumours.

Authors:  J V Pledger; A D Pearson; A W Craft; M F Laker; E J Eastham
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

Review 7.  Laboratory assessment of inflammatory bowel disease.

Authors:  I T Beck
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

8.  Antiinflammatory drug-induced small intestinal permeability: the rat is a suitable model.

Authors:  N M Davies; M R Wright; F Jamali
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

9.  Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat.

Authors:  T Mahmud; S Somasundaram; G Sigthorsson; R J Simpson; S Rafi; R Foster; I A Tavares; A Roseth; A J Hutt; M Jacob; J Pacy; D L Scott; J M Wrigglesworth; I Bjarnason
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 10.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.